DIPG Panel Discussion, page-2

Details of the PNOC DIPG study design platform discussed, paxalisib and ONC-201 method of treatment arms also discussed, currently recruiting patients very well together with new study site expansions.
Trial drug data expected early next year which can be used in company sponsored FDA ongoing discussions, with the possibility of a priority voucher available with an eventual drug approval..
Matt Dun's important research collaboration and data publication next month also discussed.
Very impressed with the dedication of Professor Sabine Mueller to quickly establish and coordinate the PNOC DIPG study to date.

Regards.